Vaccine experts report positive results on Phase 1 trial of personalized vaccine for lymphoplasmacytic lymphoma
A team of researchers from City of Hope and The University of Texas M.D. Anderson Cancer Center has reported safety and ...
The Brighterside of News on MSN6d
First-ever mRNA vaccine halts pancreatic cancer in its tracks
RNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...
Buy Rating for Evaxion Biotech Supported by Strong Clinical Results and PIONEER Platform’s Potential
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Evaxion Biotech (EVAX – Research Report) today and set a price ...
The American Journal of Managed Care3d
Can Vaccines Be Developed for MPNs? Study Examines the Challenges
Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for ...
News Medical3d
Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma
The team is also exploring additional therapies to pair with the neoantigen for more vaccine efficacy. Dr. Kwak is a paid consultant with Renhaim Inc. The neoantigen vaccine research builds upon ...
Achilles Therapeutics Announces Strategic Update
Achilles to discontinue development of TIL-based cNeT therapy––Cash position of $95.1 million as of June 30, 2024––BofA Securities engaged to ...
News Medical on MSN2d
Hope Vaccine Experts Positive on Lymphoma Trial
A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S ...
City of Hope Vaccine Experts Report Positive Results on Phase 1 Trial of Personalized Vaccine for Lymphoplasmacytic Lymphoma
A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in ...
EurekAlert!2d
City of Hope vaccine experts report positive results on Phase 1 trial of personalized vaccine for lymphoplasmacytic lymphoma
The team is also exploring additional therapies to pair with the neoantigen for more vaccine efficacy. Dr. Kwak is a paid consultant with Renhaim Inc. The neoantigen vaccine research builds upon ...